MDL 100240

Drug Profile

MDL 100240

Alternative Names: 100240; M 100240; MDL100240

Latest Information Update: 17 Mar 2009

Price : $50

At a glance

  • Originator sanofi-aventis
  • Class Antihypertensives; Benzazepines; Carboxylic acids; Heart failure therapies; Small molecules
  • Mechanism of Action ACE inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Heart failure; Hypertension

Most Recent Events

  • 11 Feb 2009 Discontinued - Phase-II for Congestive heart failure in Europe (PO)
  • 11 Feb 2009 Discontinued - Phase-II for Congestive heart failure in USA (PO)
  • 09 Feb 2005 A clinical study has been added to the adverse events and pharmacokinetics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top